Dyne Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Dyne Therapeutics, Inc. (DYN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are DYN insiders buying or selling?
In the last 12 months, Dyne Therapeutics, Inc. insiders reported 8 open-market purchases ($314.8K) and 38 sales ($168.6M) — net selling of $168.3M. Since September 2020, Trabud has recorded 209 Form 4 filings for DYN: 16 buys ($93.6M) and 193 sells ($417.2M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $45.2K by Brian S Posner (Director) on Mar 10, 2026. SEC ↗
- The most recent open-market purchase was reported on Oct 6, 2026 (12 days ago).
Key Statistics (September 2020 – Oct 6, 2026)
Total Form 4 filings
209
SEC EDGAR
Insider filers
20
Insider buys (16)
$93.6M
Insider sells (193)
$417.2M
Insider sentiment
Net sellingNet insider flow of $323.6M in net selling since September 2020, and $168.3M in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent DYN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Brian S Posner | Director | Purchase | 2.5K | $16.00 | $40.0K | SEC ↗ |
| Sep 8, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 1.1K | $23.42 | $25.4K | SEC ↗ |
| Sep 8, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 5.0K | $22.95 | $115.5K | SEC ↗ |
| Sep 8, 2026 | John Cox | CEO & President | Sale | 5.7K | $18.88 | $106.8K | SEC ↗ |
| Aug 17, 2026 | Jason P Rhodes | Director | Sale | 2.6M | $25.20 | $65.2M | SEC ↗ |
| Aug 17, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 226 | $26.28 | $5.9K | SEC ↗ |
| Aug 17, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 1.6K | $26.28 | $40.9K | SEC ↗ |
| Aug 17, 2026 | John Cox | CEO & President | Sale | 5.0K | $26.28 | $131.0K | SEC ↗ |
| Aug 17, 2026 | Erick Lucera | Chief Financial Officer | Sale | 1.8K | $26.28 | $47.2K | SEC ↗ |
| Jul 29, 2026 | Dirk Kersten | Director | Sale | 261.5K | $25.51 | $6.7M | SEC ↗ |
| Jul 8, 2026 | Jason P Rhodes | Director | Sale | 777.5K | $22.97 | $17.9M | SEC ↗ |
| Jun 30, 2026 | Jason P Rhodes | Director | Sale | 504.7K | $21.23 | $10.7M | SEC ↗ |
| Jun 26, 2026 | Erick Lucera | Chief Financial Officer | Sale | 2.4K | $20.37 | $48.1K | SEC ↗ |
| Jun 26, 2026 | Jason P Rhodes | Director | Sale | 267.8K | $21.09 | $5.6M | SEC ↗ |
| Jun 24, 2026 | Dirk Kersten | Director | Sale | 264.0K | $20.70 | $5.5M | SEC ↗ |
| Jun 22, 2026 | Dirk Kersten | Director | Sale | 84.4K | $20.10 | $1.7M | SEC ↗ |
| Jun 17, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 887 | $18.33 | $16.3K | SEC ↗ |
| Jun 17, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 145 | $18.33 | $2.7K | SEC ↗ |
| Jun 17, 2026 | John Cox | CEO & President | Sale | 2.7K | $18.33 | $49.2K | SEC ↗ |
| Jun 9, 2026 | Brian S Posner | Director | Purchase | 2.0K | $16.94 | $33.9K | SEC ↗ |
| Jun 5, 2026 | Brian S Posner | Director | Purchase | 2.5K | $17.48 | $43.7K | SEC ↗ |
| May 28, 2026 | Brian S Posner | Director | Purchase | 2.0K | $18.21 | $36.4K | SEC ↗ |
| May 22, 2026 | Brian S Posner | Director | Purchase | 2.5K | $17.12 | $42.8K | SEC ↗ |
| May 14, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 228 | $18.36 | $4.2K | SEC ↗ |
| May 14, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 1.6K | $18.36 | $28.7K | SEC ↗ |
Showing the 25 most recent of 209 Form 4 filings for Dyne Therapeutics, Inc..
Most active DYN insiders
- Dirk Kersten33 filings
- Richard William Scalzo26 filings
- Oxana Beskrovnaya22 filings
- Susanna Gatti High19 filings
- Jonathan Mcneill18 filings
Ask anything about DYN insider activity
Use Trabud's AI agent to query Dyne Therapeutics, Inc.'s Form 4 history in plain English — "Show me DYN CEO purchases this year" or compare it against any other ticker.
Open the AI agentDYN insider trading FAQ
Are Dyne Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Dyne Therapeutics, Inc. insiders reported 8 open-market purchases ($314.8K) and 38 sales ($168.6M) — net selling of $168.3M. Since September 2020, Trabud has recorded 209 Form 4 filings for DYN: 16 buys ($93.6M) and 193 sells ($417.2M). Over the full record that is net selling of $323.6M.
How many insiders trade DYN stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Dyne Therapeutics, Inc.. The most recent filing was accepted on Oct 6, 2026.
Where does Trabud get DYN insider trading data?
All DYN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.